Indication
Targeted Therapy
4 clinical trials
5 products
2 drugs
Clinical trial
A Randomized, Controlled, Multicenter Phase II Clinical Study of Sintilimab Combined With Fruquintinib/Regorafenib ± Radiotherapy for Third-line Treatment of Advanced Metastatic Colorectal Cancer.Status: Recruiting, Estimated PCD: 2026-10-01
Product
SintilimabClinical trial
Matched Targeted Therapy (MTT) Recommendation for Patients With Recurrent, Refractory, or High Risk Leukemias and Myelodysplastic SyndromeStatus: Active (not recruiting), Estimated PCD: 2022-05-16
Product
Leukemia ProfilingClinical trial
A Prospective Cohort, Open, Phase II Clinical Study of Chidamide/Everolimus Combined With Endocrine Therapy for PIK3CA Wild-type/Mutant Hormone Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative Advanced Breast CancerStatus: Recruiting, Estimated PCD: 2026-07-15
Product
EverolimusDrug
TucidinostatProduct
Endocrine therapyProduct
Ovarian function suppressionClinical trial
AZD9291, an Irreversible EGFR-TKI, in Relapsed EGFR-mutated Non-small Cell Lung Cancer Patients Previously Treated With an EGFR-TKI, Coupled to Extensive Translational StudiesStatus: Active (not recruiting), Estimated PCD: 2023-06-01
Drug
Osimertinib